Related Experiment Video
Updated: Aug 18, 2026
Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
Published on: July 8, 2011
Transfection of human monocyte-derived dendritic cells with CpG oligonucleotides
Michael Erhardt1, Marcus Gorschlüter, Jens Sager
1Department of Internal Medicine I, University of Bonn, Germany.
Abstract:
Monocyte-derived dendritic cells (mDC), the most frequently applied DC subset in clinical studies, which can be obtained easily from peripheral blood monocytes after incubation with GM-CSF and IL-4, have not been clearly demonstrated to be activated by CpG oligodeoxynucleotides (ODN). The development of novel molecular strategies - such as the use of CpG-ODN - to increase immunological functions and thus improve the therapeutic efficiency of mDC vaccines in the treatment of malignant diseases is highly desirable. CpG-ODN need to be internalized into specific intracellular compartments to be active. Therefore, we applied electroporation and lipofection and compared these techniques with incubation to overcome possible defects in localization. Conditions of CpG-ODN transfection of these cells were optimized using fluorescein-marked ODN 2216. We were able to achieve high transfection efficiencies with various methods of delivery. However, we did not observe increased expression of maturation-associated and functionally relevant surface antigens (CD14, HLA-DR, CD40, CD83, CD80 and CD86), significant secretion of IL-12 and IFN-alpha in culture supernatant, or enhanced antitumour activation of cytokine-induced killer cells. In conclusion, our results show that non-viral transfection of CpG-ODN is not sufficient to overcome resistance of mDC to CpG activation.
Insights
Transfecting monocyte-derived dendritic cells (mDCs) with CpG oligodeoxynucleotides (ODN) via electroporation or lipofection did not enhance their activation. Non-viral transfection methods failed to overcome mDC resistance to CpG stimulation for cancer immunotherapy.
Area of Science:
- Immunology
- Cell Biology
- Cancer Therapy
Background:
- Monocyte-derived dendritic cells (mDCs) are crucial in cancer vaccines.
- Activating mDCs with CpG oligodeoxynucleotides (ODN) could improve therapeutic efficiency.
- CpG-ODN require intracellular delivery for activation, posing a delivery challenge.
Purpose of the Study:
- To investigate the efficacy of non-viral transfection methods for delivering CpG-ODN into mDCs.
- To determine if enhanced CpG-ODN delivery activates mDCs and improves anti-tumor responses.
Main Methods:
- Monocyte-derived dendritic cells (mDCs) were generated from peripheral blood monocytes.
- Electroporation and lipofection were used to transfect mDCs with CpG-ODN.
- Transfection efficiency was optimized using fluorescein-marked ODN 2216.
- Expression of maturation markers, cytokine secretion (IL-12, IFN-alpha), and anti-tumor activity were assessed.
Main Results:
- High transfection efficiencies were achieved using electroporation and lipofection.
- No significant increase in maturation-associated surface antigens (CD14, HLA-DR, CD40, CD83, CD80, CD86) was observed.
- No significant secretion of IL-12 and IFN-alpha was detected in the supernatant.
- Enhanced anti-tumor activation of cytokine-induced killer cells was not observed.
Conclusions:
- Non-viral transfection of CpG-ODN into mDCs does not overcome their inherent resistance to CpG activation.
- Current methods are insufficient to enhance mDC immune function for improved cancer vaccine efficacy.
- Further research is needed to develop effective strategies for CpG-ODN delivery and mDC activation.
